San Diego’s Beacon Discovery formed a multi-year drug discovery collaboration with Takeda Pharmaceutical Company centered on gastrointestinal disorders.
San Diego’s Okogen received $10 million in Series A funding to advance the company’s lead candidate for viral conjunctivis, commonly known as pink eye.
Ionis Pharmaceuticals in Carlsbad Reported $508 million in 2017 revenue, a 46.3 percent increase over the previous year, driven by rising drug royalties.
Spine surgery and medical device maker NuVasive reported revenue of $271.1 million in the fourth quarter for flat year-over-year growth.
MEDICINE: Big Players Bail, But Midsize Cos. Aim for Next Big Thing
Amid big pharma’s waning commitment to neurological disorders like Alzheimer’s, San Diego startups and midstage biotechs see opportunity.
MEDICINE: System Is Betting On Treatment Strategies Success
UC San Diego Health has launched a Medicare program that brings the potential for health system savings — that is, if it can meet care and cost requirements.
With DeFord’s appointment, the board will have 10 directors, nine of whom are independent.
Carlsbad’s Ionis Pharmaceuticals has licensed a kidney drug to British giant AstraZeneca, earning $30 million upfront and the potential for $300 million in development and regulatory milestone payments.
Life sciences entrepreneur Dena Marranuci, who leads corporate development and research and development at Truvian Sciences, will moderate a discussion about raising early-stage capital.
Medical staffing company AMN Healthcare reported 2017 fourth quarter revenue of $509 million, a 4 percent year-over-year increase.
San Diego’s Tandem Diabetes Care inked a European distribution deal with Rubin Medical, meaning its insulin pumps will be sold outside the U.S. for the first time.
DEVICES: Company Gains Advantage By Partnering With Insurer
Dexcom aspires to widen its reach beyond Type 1 diabetes. Recently, the San Diego company took a big step toward the goal.
The firm has two San Diego companies in its eight-company portfolio.
A first-ever test from San Diego’s Banyan Biomarkers to help doctors diagnose traumatic brain injuries has won Federal Drug Administration approval.